378 related articles for article (PubMed ID: 24931325)
1. Caffeine for apnea of prematurity: a neonatal success story.
Kreutzer K; Bassler D
Neonatology; 2014; 105(4):332-6. PubMed ID: 24931325
[TBL] [Abstract][Full Text] [Related]
2. Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial.
Schmidt B
Biol Neonate; 2005; 88(3):208-13. PubMed ID: 16210843
[TBL] [Abstract][Full Text] [Related]
3. Methylxanthine use for apnea of prematurity among an international cohort of neonatologists.
Abu Jawdeh EG; O'Riordan M; Limrungsikul A; Bandyopadhyay A; Argus BM; Nakad PE; Supapannachart S; Yunis KA; Davis PG; Martin RJ
J Neonatal Perinatal Med; 2013; 6(3):251-6. PubMed ID: 24246598
[TBL] [Abstract][Full Text] [Related]
4. Caffeine therapy for apnea of prematurity.
Schmidt B; Roberts RS; Davis P; Doyle LW; Barrington KJ; Ohlsson A; Solimano A; Tin W;
N Engl J Med; 2006 May; 354(20):2112-21. PubMed ID: 16707748
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of caffeine for apnea of prematurity.
Dukhovny D; Lorch SA; Schmidt B; Doyle LW; Kok JH; Roberts RS; Kamholz KL; Wang N; Mao W; Zupancic JA;
Pediatrics; 2011 Jan; 127(1):e146-55. PubMed ID: 21173002
[TBL] [Abstract][Full Text] [Related]
6. Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.
Schmidt B; Roberts RS; Anderson PJ; Asztalos EV; Costantini L; Davis PG; Dewey D; D'Ilario J; Doyle LW; Grunau RE; Moddemann D; Nelson H; Ohlsson A; Solimano A; Tin W;
JAMA Pediatr; 2017 Jun; 171(6):564-572. PubMed ID: 28437520
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of caffeine therapy for apnea of prematurity.
Schmidt B; Roberts RS; Davis P; Doyle LW; Barrington KJ; Ohlsson A; Solimano A; Tin W;
N Engl J Med; 2007 Nov; 357(19):1893-902. PubMed ID: 17989382
[TBL] [Abstract][Full Text] [Related]
8. Current options in the management of apnea of prematurity.
Bhatia J
Clin Pediatr (Phila); 2000 Jun; 39(6):327-36. PubMed ID: 10879934
[TBL] [Abstract][Full Text] [Related]
9. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Schmidt B; Anderson PJ; Doyle LW; Dewey D; Grunau RE; Asztalos EV; Davis PG; Tin W; Moddemann D; Solimano A; Ohlsson A; Barrington KJ; Roberts RS;
JAMA; 2012 Jan; 307(3):275-82. PubMed ID: 22253394
[TBL] [Abstract][Full Text] [Related]
10. Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial.
Skouroliakou M; Bacopoulou F; Markantonis SL
J Paediatr Child Health; 2009 Oct; 45(10):587-92. PubMed ID: 19751376
[TBL] [Abstract][Full Text] [Related]
11. Caffeine: an evidence-based success story in VLBW pharmacotherapy.
Dobson NR; Hunt CE
Pediatr Res; 2018 Sep; 84(3):333-340. PubMed ID: 29983414
[TBL] [Abstract][Full Text] [Related]
12. National and international guidelines for neonatal caffeine use: Are they evidenced-based?
Eichenwald EC
Semin Fetal Neonatal Med; 2020 Dec; 25(6):101177. PubMed ID: 33214064
[TBL] [Abstract][Full Text] [Related]
13. Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity.
Khurana S; Shivakumar M; Sujith Kumar Reddy GV; Jayashree P; Ramesh Bhat Y; Lewis LES
J Neonatal Perinatal Med; 2017; 10(4):355-362. PubMed ID: 29286928
[TBL] [Abstract][Full Text] [Related]
14. Controversies surrounding xanthine therapy.
Millar D; Schmidt B
Semin Neonatol; 2004 Jun; 9(3):239-44. PubMed ID: 15050217
[TBL] [Abstract][Full Text] [Related]
15. Doxapram Treatment for Apnea of Prematurity: A Systematic Review.
Vliegenthart RJ; Ten Hove CH; Onland W; van Kaam AH
Neonatology; 2017; 111(2):162-171. PubMed ID: 27760427
[TBL] [Abstract][Full Text] [Related]
16. Caffeine for apnea of prematurity.
Bancalari E
N Engl J Med; 2006 May; 354(20):2179-81. PubMed ID: 16707756
[No Abstract] [Full Text] [Related]
17. Neurobehavioral Outcomes 11 Years After Neonatal Caffeine Therapy for Apnea of Prematurity.
Mürner-Lavanchy IM; Doyle LW; Schmidt B; Roberts RS; Asztalos EV; Costantini L; Davis PG; Dewey D; D'Ilario J; Grunau RE; Moddemann D; Nelson H; Ohlsson A; Solimano A; Tin W; Anderson PJ;
Pediatrics; 2018 May; 141(5):. PubMed ID: 29643070
[TBL] [Abstract][Full Text] [Related]
18. Early childhood developmental follow-up of infants with GMH/IVH: effect of methylxanthine therapy.
Ment LR; Scott DT; Ehrenkranz RA; Duncan CC
Am J Perinatol; 1985 Jul; 2(3):223-7. PubMed ID: 4015773
[TBL] [Abstract][Full Text] [Related]
19. Management of apnea in infants.
Kriter KE; Blanchard J
Clin Pharm; 1989 Aug; 8(8):577-87. PubMed ID: 2670399
[TBL] [Abstract][Full Text] [Related]
20. Neonatal Caffeine Treatment and Respiratory Function at 11 Years in Children under 1,251 g at Birth.
Doyle LW; Ranganathan S; Cheong JLY
Am J Respir Crit Care Med; 2017 Nov; 196(10):1318-1324. PubMed ID: 28707987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
